ENBIOSIS IS NOW OFFICIALLY THE FIRST CLINICALLY PROVEN AI-BASED SOLUTION FOR GUT HEALTH

78% Success
in 6 Weeks

* Impact factor 11.7
* H-Index of 82

Full Article

78% Success
in 6 Weeks

FULL ARTICLE

* Impact factor 11.7
* H-Index of 82

Irritable Bowel Syndrome

Irritable bowel syndrome (IBS), also known as spastic colon, is a functional rather than a structural disorder with multifactorial pathogenesis. IBS significantly lowers the quality of life of the aected individuals.

IBS is one of the most common chronic functional bowel disorder in adults. 11% of the world’s population are estimated to suer from IBS. This rate varies between 1.1% and 45.0% on a country-by-country basis.

Microbiome-based Approach On IBS

Extensive research over the past decade has proven that the biological diversity of the gut microbiome and a disruption in the balance of the ecosystem (dysbiosis) play an important role in the pathogenesis of IBS.

At ENBIOSIS Biotechnology, we analyze the gut microbiome using artificial intelligence technologies and recommend micro and macro nutrients that can modulate the microbiome towards a target state. We aim to improve gut microbiome profile by selectively feeding the gut bacteria with the nutrients specific to the individual microbiome needs.

IBS CLINICAL STUDY

ENBIOSIS clinical study demonstrated a 78% success rate on IBS. It is the first and only successful IBS management that utilized microbiome-specific personalized nutrition recommendations.

 

CONTACT US

Please fill out the form to learn more. We’ll be in touch as soon as possible.